Glucotrack, Inc. — Form 8-K
Filed September 23, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Glucotrack Inc. (market cap ~$5.4M) completed a strategic business combination with Lōkahi Therapeutics on July 14, 2026. Post-merger, Glucotrack Technologies operates as a wholly owned subsidiary focused on continuous blood glucose monitoring, while Lōkahi Therapeutics—now the parent company's core business—focuses on acquiring clinical-stage assets and advancing LT-100, a biologic for osteoarthritis knee pain. Lōkahi operates an 'ai²' platform identifying opportunities across 12,000+ abandoned pharmaceutical programs through 14+ university partners; targeting LT-100 trial initiation imminently.
Why this rating
Material structural reorganization and refocus post-merger; $5.4M company pivoting strategy from glucose monitoring to drug development. LT-100 trial timing and capital requirements are critical. Execution risk is high; near-term impact unclear pending Series A conversion and trial data.
Price action (we called it neutral)
before filing · preread $2.21 ▼ 0.82% | at our read · unknown $2.23 | +10 min · unknown $2.17 ▼ 2.69% | +30 min · unknown $2.10 ▼ 5.61% | +1 hr pending | +4 hrs pending |
The stock had already moved +0.82% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.